These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 24284224)

  • 1. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
    Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
    Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium.
    Yu M; Yang JX; Wu M; Lang JH; Huo Z; Shen K
    Fertil Steril; 2009 Dec; 92(6):2122-4. PubMed ID: 19591991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
    Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
    Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fertility-sparing treatment of endometrial cancer precursors among young women: a reproductive point of view.
    Ricciardi E; Maniglio P; Frega A; Marci R; Caserta D; Moscarini M
    Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1934-7. PubMed ID: 23242719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of pregnancy outcome after fertility-preserving treatment among women with atypical endometrial hyperplasia or endometrial carcinoma].
    Xiao ZR; Lu Q; Zhou R; Wang YQ; Liang WY; Liu HX; Tang HR; Wu GZ; Liu XS; Zhang H; Ren Y; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2020 Dec; 55(12):857-864. PubMed ID: 33355761
    [No Abstract]   [Full Text] [Related]  

  • 7. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
    Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
    Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
    Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
    Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.
    De Marzi P; Bergamini A; Luchini S; Petrone M; Taccagni GL; Mangili G; Colombo G; Candiani M
    J Minim Invasive Gynecol; 2015; 22(7):1178-82. PubMed ID: 26092080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.
    Gunderson CC; Fader AN; Carson KA; Bristow RE
    Gynecol Oncol; 2012 May; 125(2):477-82. PubMed ID: 22245711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fertility preserving management of early endometrial cancer in a patient cohort at the department of women's health at the university of Tuebingen.
    Andress J; Pasternak J; Walter C; Kommoss S; Krämer B; Hartkopf A; Brucker SY; Schönfisch B; Steinmacher S
    Arch Gynecol Obstet; 2021 Jul; 304(1):215-221. PubMed ID: 33606091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fertility-sparing re-treatment for endometrial cancer and atypical endometrial hyperplasia patients with progestin-resistance: a retrospective analysis of 61 cases.
    Chen J; Cao D
    World J Surg Oncol; 2024 Jun; 22(1):169. PubMed ID: 38918837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.
    Kudesia R; Singer T; Caputo TA; Holcomb KM; Kligman I; Rosenwaks Z; Gupta D
    Am J Obstet Gynecol; 2014 Mar; 210(3):255.e1-4. PubMed ID: 24211482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.
    Zhou R; Yang Y; Lu Q; Wang J; Miao Y; Wang S; Wang Z; Zhao C; Wei L
    Gynecol Oncol; 2015 Dec; 139(3):424-8. PubMed ID: 26428941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women.
    Shan BE; Ren YL; Sun JM; Tu XY; Jiang ZX; Ju XZ; Zang RY; Wang HY
    Arch Gynecol Obstet; 2013 Nov; 288(5):1115-23. PubMed ID: 23644919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia.
    Wang Y; Zhou R; Wang H; Liu H; Wang J
    Int J Gynecol Cancer; 2019 May; 29(4):699-704. PubMed ID: 30826750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
    Yang B; Xu Y; Zhu Q; Xie L; Shan W; Ning C; Xie B; Shi Y; Luo X; Zhang H; Chen X
    Gynecol Oncol; 2019 Apr; 153(1):55-62. PubMed ID: 30674421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer.
    He Y; Wang Y; Zhou R; Wang J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1902-1907. PubMed ID: 33051245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer.
    Park JY; Seong SJ; Kim TJ; Kim JW; Bae DS; Nam JH
    Gynecol Oncol; 2017 Jul; 146(1):39-43. PubMed ID: 28526167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option.
    Gadducci A; Spirito N; Baroni E; Tana R; Genazzani AR
    Gynecol Endocrinol; 2009 Oct; 25(10):683-91. PubMed ID: 19562604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.